The possibility of using extracts of grape red leaves for the outpatient treatment of venous thromboembolic complications

Medvedev A.P.; Nemirova S.V.; Avetisian E.A.

doi:https://doi.org/

Medvedev A.P.

Nizhegorodskaia gosudarstvennaia meditsinskaia akademiia

Nemirova S.V.

Nizhegorodskaia gosudarstvennaia meditsinskaia akademiia

Avetisian E.A.

Nizhegorodskaia gosudarstvennaia meditsinskaia akademiia

The possibility of using extracts of grape red leaves for the outpatient treatment of venous thromboembolic complications

Authors:

Medvedev A.P., Nemirova S.V., Avetisian E.A.

More about the authors

Journal: Journal of Venous Disorders. 2013;7(3): 34‑39

Read: 2118 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Medvedev AP, Nemirova SV, Avetisian EA. The possibility of using extracts of grape red leaves for the outpatient treatment of venous thromboembolic complications. Journal of Venous Disorders. 2013;7(3):34‑39. (In Russ.)

Подписка 2026 Флебология (Journal of Venous Disorders)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Positive Predictive Value of the Wells Score in Diagnosis of Deep Vein Thrombosis: Results of Bayesian Analysis. Journal of Venous Disorders. 2024;(4):274-282

Outpatient Management of Venous Thromboembolism in Acute Phase. Journal of Venous Disorders. 2024;(4):328-338

Asplenia — a new cause of thrombosis in pregnant women?. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):71-76

Hemostasis disorders during neoadjuvant therapy in patients with breast cancer. P.A. Herzen Journal of Oncology. 2025;(3):39-44

Efficacy and Safety of the Oral Anticoagulant DIMOLEGIN Compared to Enoxaparin Sodium for the Prevention of Venous Thromboembolism Following Major Joint Replacement Surgery (hip or knee arthroplasty): A Randomized, Double-Blind, Multicenter Trial. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(5):577-585

Abstract:

Aim. To estimate the effectiveness of standard preparations of the extracts of grape red leaves introduced into combined therapy of the patients presenting with venous thromboembolic complications at the stage of outpatient treatment. Material and methods. The results of the treatment of 3 groups of the patients who had suffered pulmonary thromboembolism were available for the analysis. Combined outpatient treatment of the patients of group 1 was supplemented by the intake of diosmin-containing phlebotropic pharmaceuticals. The patients of group 2 were given standard preparations of the extracts of grape red leaves, those of group 3 did not use angioprotectors. The results of the three therapeutic modalities were compared upon discharge from the hospital and after a 3-month follow-up period. The outcome of the treatment was estimated based on dynamics of personal complaints ( based on the visual-analog scale), the quality of patients' life (based on the SF-36 questionnaire), clinical status (general examination, measurements of malleolar circumference), and parameters of venous hemodynamics (data of ultrasound studies). Results. The patients of groups 1 and 2 showed similar positive dynamics of subjective and objective characteristics that prevailed over irregular dynamics of the same characteristics in the patients of group 3. The patients of the first two groups reported alleviation of pain and oedematous syndromes that was confirmed by decreased malleolar circumference (by 19,7±0,2 mm and 19,7±0,2 mm respectively compared with 10,4±1,6 mm ion group 3). The diameter of common femoral vein decreased whereas the averaged linear velocity in the spectrum increased (p<0.03). The slowest recovery rate of venous hemodynamics and major health status characteristics was documented among the patients of group 3. Conclusion. The present study has demonstrated that the combined outpatient treatment of the patients presenting with venous thromboembolic complications with the use of standard preparations of the extracts of grape red leaves is comparable with therapy using diosmin-containing phlebotropic pharmaceuticals in terms of effectiveness and safety. The beneficial effect of both therapeutic modalities is superior to that of isolated anticoagulation treatment.

Keywords:

venous thromboembolism

out-patient treatment

angioprotectors

Authors:

Medvedev A.P.

Nizhegorodskaia gosudarstvennaia meditsinskaia akademiia

Nemirova S.V.

Nizhegorodskaia gosudarstvennaia meditsinskaia akademiia

Avetisian E.A.

Nizhegorodskaia gosudarstvennaia meditsinskaia akademiia

Close metadata

References:

Savel'ev V.S., Gologorskiy V.A., Kirienko A.I. Flebologiya: Rukovodstvo dlya vrachey. Pod red. B.C. Savel'eva [Phlebology. Guidelines for physicians. Ed. V.S. Saveliev]. M: Meditsina 2001.
Anderson F.A. et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 933-938.
White R.H. The epidemiology of venous thromboembolism. Circulation 2003; 107: 23: Suppl 1: 14-18.
Nordstrom M. et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-160.
Ramaswami G., Nicolaides A. Natural history of vein thrombosis. Prevention of vonous thromboembolism. Eds. D. Berquist, A.J. Comelota, A.N. Nicolaides et al. Med Orton 1994;109-119.
Kirienko A.I., Andriyashkin V.V., Iskhakov Ya.G., Zlatovratskiy A.G. Reabilitatsiya bol'nykh, perenesshikh tromboz glubokikh ven [Rehabilitation of the patients after deep vein thrombosis]. Spravochnik poliklinicheskogo vracha 2003; 3: 25-28.
Bergqvist D. Optimal management of deep vein thrombosis. Vascular surgery highlights 1999-2000. Oxford 2000; 39-46.
Petrini O., Ambrosetti L., Shafer E. Antistaks - novyy preparat vybora dlya profilaktiki i lecheniya khronicheskoy venoznoy nedostatochnosti. Klinicheskie aspekty lecheniya khronicheskoy venoznoy nedostatochnosti [Antistacs - the new drug of choice for the prevention and treatment of chronic venous insufficiency. Clinical aspects of the treatment of chronic venous insufficiency]. RMZh 2005; 13: 9: 595-598.
Pittler М.Н. Complementary therapies for chronic venous insufficiency. Focus on Alternative and Complementary. Therapies 2001; 6:3-5.
Bogachev V.Yu. Sistemnaya farmakoterapiya khronicheskoy venoznoy nedostatochnosti nizhnikh konechnostey. Sovremennoe sostoyanie voprosa [Systemic pharmacotherapy of chronic venous insufficiency in the lower extremities. State-of-the-art]. RMZh 2004; 17: 994-999.
Kiesewetter H. et al. Efficacy of Orally Administered extracts of Red Vine Leaf AS 195 (folia vitis viniferae) in Chronic Venous Insufficiency (Stages I-II). A randomised, double-blind,placebo- controlled trial). Arzneim-Forsch Drug Res 2000; 50: 1: 109-117.
Grant S. et al. A Comparison of the Reproducibility and the Sensitivity to Change of Visual Analogue Scales, Borg Scales, and Likert Scales in Normal Subjects During Submaximal Exercise. Chest 1999; 116: 1208-1217.
Aronov D.M., Zaytsev V.P. Metodika otsenki kachestva zhizni bol'nykh s serdechno-sosudistymi zabolevaniyami [A method for the assessment of the quality of life in the patients presenting with cardiovascular diseases]. Kardiologiya 2002; 5: 93-95.
Ware J.E., Sherboume C.D. The MOS 36-Item short-form health survey. Med Care 1992; 30: 6: 473-483.
Partsch H. A new classification scheme of chronic venous disease in the lower extremities. The "СЕАР"'-sistem. Phlebolymphology 1995; 10: IS-IS.
Kirienko A.I., Panchenko E.N., Andriyashkin V.V. Venoznyy tromboz v praktike terapevta i khirurga [Venous thrombosis in the practical work of a therapist and a surgeon]. M: Planida 2012.
Task Force Report. Guidelines on diagnosis and management of acute pulmonary embolism. European Society of Cardiology. Eur Heart J 2004; 21: 1301-1336.
Huk I., Brovkovich V., Nanobashvili I. et al. Bioflavonoids quercetin scavenges superoxide and increases nitric oxide concentration in ischemicreperfusion injury: an experimental study. Br Heart J 1996; 85: 8: 1080-1085.